UNLIMITED TURBO LONG - ASTRAZENECA | Delayed Deutsche Boerse AG 08:21:12 2024-06-17 EDT | ||
| 4.66 EUR | -1.69% |
|
| Current month | +9.22% | ||
| 1 month | +7.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 4.66 | -1.69% |
| 24-06-14 | 4.74 | +3.72% |
| 24-06-13 | 4.57 | -1.72% |
| 24-06-12 | 4.65 | +1.53% |
| 24-06-11 | 4.58 | -4.98% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 08:21 am
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PN3EBK |
| ISIN | DE000PN3EBK8 |
| Date issued | 2023-05-16 |
| Strike | 859,369 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.68 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.9 € |
|---|---|
| Lowest since issue | 1.3 € |
| Spread | 0.01 € |
| Spread % | 0.21% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Certificates
- Certificat
